Lv3
400 积分 2023-02-27 加入
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
2个月前
已完结
Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study
3个月前
已完结
Correspondence to viewpoint ‘Defining refractory rheumatoid arthritis’ by Buch
3个月前
已完结
Challenges in the treatment of Rheumatoid Arthritis
3个月前
已完结
Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis
3个月前
已完结
Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey
3个月前
已完结
Defining refractory rheumatoid arthritis
3个月前
已完结
Macrophage requirements for abatacept response in rheumatoid arthritis
3个月前
已完结
Macrophage requirements for abatacept response in rheumatoid arthritis
4个月前
已完结
Changes in metabolic parameters and serum YKL-40 levels in Chinese rheumatoid arthritis patients during tocilizumab therapy
1年前
已完结
皖公网安备34019202002308
